{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:40:49Z","timestamp":1792057249490,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADC Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03169-9","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:22:19Z","timestamp":1743358939000},"page":"2445-2464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed\/Refractory DLBCL After\u00a0\u2265\u00a02 Lines of Therapy: Matching-Adjusted Indirect Comparison"],"prefix":"10.1007","volume":"42","author":[{"given":"Koo","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Chiodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Macmillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"2","key":"3169_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","volume":"31","author":"A Rosenthal","year":"2017","unstructured":"Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37\u201342.","journal-title":"Blood Rev"},{"issue":"12","key":"3169_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"16","key":"3169_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"1","key":"3169_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3169_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216\u201321.","journal-title":"Bone Marrow Transplant"},{"key":"3169_CR6","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/blood-2019-123664","volume":"134","author":"J Radford","year":"2019","unstructured":"Radford J, White E, Castro FA, Chaturvedi A, Spielewoy N, Gibb A, et al. Treatment patterns and outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma: experience from a single UK centre. Blood. 2019;134:2917.","journal-title":"Blood"},{"issue":"3","key":"3169_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/13696998.2019.1702990","volume":"23","author":"M Mounie","year":"2020","unstructured":"Mounie M, Costa N, Conte C, Petiot D, Fabre D, Despas F, et al. Real-world costs of illness of Hodgkin and the main B-cell non-Hodgkin lymphomas in France. J Med Econ. 2020;23(3):235\u201342.","journal-title":"J Med Econ"},{"issue":"1","key":"3169_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22\u201332.","journal-title":"Blood"},{"issue":"3","key":"3169_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","volume":"31","author":"C Sarkozy","year":"2018","unstructured":"Sarkozy C, Sehn LH. Management of relapsed\/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209\u201316.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"18","key":"3169_CR10","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737\u201346.","journal-title":"Blood"},{"issue":"10","key":"3169_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/03007995.2021.1957806","volume":"37","author":"J Xie","year":"2021","unstructured":"Xie J, Wu A, Liao L, Nastoupil LJ, Du EX, Noman A, et al. Characteristics and treatment patterns of relapsed\/refractory diffuse large B-cell lymphoma in patients receiving >\/=3 therapy lines in post-CAR-T era. Curr Med Res Opin. 2021;37(10):1789\u201398.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"3169_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. Hemasphere. 2021;5(2): e524.","journal-title":"Hemasphere"},{"key":"3169_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.915342","volume":"13","author":"C Jommi","year":"2022","unstructured":"Jommi C, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions. Front Pharmacol. 2022;13: 915342.","journal-title":"Front Pharmacol"},{"key":"3169_CR14","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26 Suppl 5","author":"H Tilly","year":"2015","unstructured":"Tilly H, GomesdaSilva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v116\u201325.","journal-title":"Ann Oncol"},{"issue":"1","key":"3169_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14136","volume":"174","author":"S Chaganti","year":"2016","unstructured":"Chaganti S, Illidge T, Barrington S, McKay P, Linton K, Cwynarski K, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43\u201356.","journal-title":"Br J Haematol"},{"key":"3169_CR16","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphoma. Version January 2024. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 3 Apr 2024."},{"key":"3169_CR17","unstructured":"National Institute for Health and Care Excellence. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic therapies\u2014final scope. 2023. https:\/\/www.nice.org.uk\/guidance\/gid-ta10831\/documents\/final-scope. Accessed 31 Jan 2023."},{"issue":"4","key":"3169_CR18","first-page":"1184","volume":"109","author":"PF Caimi","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109(4):1184\u201393.","journal-title":"Haematologica"},{"issue":"8","key":"3169_CR19","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1016\/j.clml.2022.04.006","volume":"22","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, et al. Matching-adjusted indirect comparison of the efficacy of loncastuximab tesirine versus treatment in the chemoimmunotherapy era for relapsed\/refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(8):e738\u201344.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"3169_CR20","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jval.2024.10.219","volume":"27","author":"K Wilson","year":"2024","unstructured":"Wilson K, Chiodi F, Paine A, Hakimi Z, Mappa S, Crowe V, et al. CO143 loncastuximab tesirine versus glofitamab for the treatment of relapsed\/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy: a matching-adjusted indirect comparison. Value in Health. 2024;27(12):S41.","journal-title":"Value in Health."},{"key":"3169_CR21","doi-asserted-by":"publisher","first-page":"e006348e","DOI":"10.1097\/01.HS9.0000971512.00634.8e","volume":"8","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Fox C, Wang A, Sail K, Alshreef A, Moran M, et al. P1154: efficacy of subcutaneous epcoritamab vs. axi-cel in R\/R DLBCL CAR T-naive and CAR T-eligible patients: an indirect comparison. Hemasphere. 2023;8:e006348e.","journal-title":"Hemasphere."},{"key":"3169_CR22","unstructured":"Phillippo DM, Ades AE, Dias S, S P, Abrams KR, Welton NJ. NICE DSU TSD 18: Methods for population-adjusted indirect comparisons in submissions to NICE. 2016. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/population-adjusted. Accessed 03 Feb 2023."},{"issue":"SUPPL 1","key":"3169_CR23","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1182\/blood-2021-148730","volume":"138","author":"JP Alderuccio","year":"2021","unstructured":"Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, et al. Clinical characteristics and responses of patients with relapsed or refractory high-grade B-cell lymphoma treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood. 2021;138(SUPPL 1):3575.","journal-title":"Blood"},{"issue":"6","key":"3169_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3169_CR25","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","volume":"22","author":"PF Caimi","year":"2022","unstructured":"Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, et al. The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy. Clin Lymphoma Myeloma Leuk. 2022;22(5):e335\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3169_CR26","unstructured":"Zinzani P, Caimi P, Carlo-Stella C, Ai W, Alderuccio JP, Ardeshna K, et al. LOTIS-2 follow-up analysis: updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma. Presented at the international conference on malignant lymphoma (IMCL) virtual congress. 2021. https:\/\/www.adctmedical.com\/wp-content\/uploads\/2021\/06\/Zinzani-et-al.-LOTIS-2-follow-up-analysis-Updated-results-from-a-Phase-2-study-of-lonca-in-RR-DLBCL.pdf."},{"issue":"SUPPL 2","key":"3169_CR27","first-page":"252","volume":"39","author":"PL Zinzani","year":"2021","unstructured":"Zinzani PL, Caimi PF, Carlo-Stella C, Ai W, Alderuccio JP, Ardeshna KM, et al. Lotis 2 follow-up analysis: updated results from a phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma. Hematol Oncol. 2021;39(SUPPL 2):252\u20134.","journal-title":"Hematol Oncol"},{"issue":"2","key":"3169_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"LH Sehn","year":"2022","unstructured":"Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533\u201343.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"3169_CR29","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1182\/blood-2022-167753","volume":"140","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Liao L, Wilson L, Howarth A, Flores C, Chen L. Real-world outcomes in relapsed\/refractory DLBCL patients who received polatuzumab vedotin PLUS bendamustine and rituximab or tafasitamab plus lenalidomide by line of therapy (poster abstract). Blood. 2022;140(Supplement 1):8058\u201360.","journal-title":"Blood"},{"issue":"1","key":"3169_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00277-022-05052-x","volume":"102","author":"MS Dal","year":"2023","unstructured":"Dal MS, Ulu BU, Uzay A, Akay OM, Besisik S, Yenerel MN, et al. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey. Ann Hematol. 2023;102(1):133\u201340.","journal-title":"Ann Hematol"},{"issue":"10","key":"3169_CR31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"3169_CR32","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case#synthesis-of-evidence-on-health-effects. Accessed May 2024."},{"key":"3169_CR33","unstructured":"R project. The R project for statistical computing. https:\/\/www.r-project.org\/. Accessed Jan 2025."},{"issue":"27","key":"3169_CR34","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3169_CR35","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","volume":"27","author":"PL Zinzani","year":"2021","unstructured":"Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, et al. RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2021;27(22):6124\u201334.","journal-title":"Clin Cancer Res"},{"key":"3169_CR36","unstructured":"National Institute for Health and Care Excellence. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]. 2022. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10645. Accessed 9 Nov 2022."},{"issue":"7414","key":"3169_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"1","key":"3169_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55\u201379.","journal-title":"Res Synth Methods"},{"issue":"2","key":"3169_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193\u2013206.","journal-title":"Psychol Methods"},{"issue":"6","key":"3169_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clml.2021.11.011","volume":"22","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and clinical outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma who received at least 3 lines of therapies. Clin Lymphoma Myeloma Leuk. 2022;22(6):373\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3169_CR41","unstructured":"Sobi. Data on file: clinical interviews, summary report. 2023."},{"issue":"19","key":"3169_CR42","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/molecules26195847","volume":"26","author":"JTW Tong","year":"2021","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. 2021;26(19):5847.","journal-title":"Molecules"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03169-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03169-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03169-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:51:01Z","timestamp":1744858261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03169-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03169-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koo Wilson, Zalmai Hakimi, Francesca Chiodi, Silvia Mappa, Daniel Eriksson are employees of Swedish Orphan Biovitrum AB. Abby Paine and Victoria Ward are employees, and Tom Macmillan was an employee of Source Health Economics which received consultancy fees for the systematic literature review and statistical analyses presented in this manuscript. Tom Macmillan is now affiliated with Cytel.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"LOTIS-2 was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. Institutional review boards at participating institutions approved the study protocol and amendments. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}